Studies on formulation development and evaluation of novel polymeric nanoparticulate drug delivery system of Etoposide

Abstract

Preformulation study was performed for etoposide drug. The initial part of work was started from the identification of drug. Identification of drug was determined by melting point, solubility, FTIR Spectroscopy, UV Spectroscopy and Assay. Nine batches of nanoparticles (F1, F2, F3, F4, F5, F6, F7, F8, and F9) were prepared by using Eudragit EPO and pluronic F-68 with 32 factorial design by nanoprecipitation method. The tissue distributions studies shown that etoposide loaded nanoparticles exhibited favored drug targeting to liver followed by spleen, lungs, kidney and brain. It was also shown that, as compared to pure drug, higher drug concentration was found and targeted to the organs like the liver and lungs after administering the dose in the form of nanosuspension. This may lead to endorsed high macrophage load in these organs besides larger size of liver as compared to spleen and lungs. Recently, nanoparticles containing etoposide have been reported to be useful, subsequently they allow entering the cancer cell and act as an intracellular anti-cancer drug reservoir. A newer approach is proposed here by the use of novel polymeric nanoparticles of etoposide. The improved drug release rate due to its reduced particle size and improved oral bioavailability. Etoposide widely prescribing drug for the treatment of various tumours. Though, the clinical usefulness by oral administration is compared by its biopharmaceutical properties. Therefore, the study concluded that novel polymeric nanoparticles of etoposide are most useful to enhance oral bioavailability and targeting the cancer cells. In future the clinical studies using human volunteers are required to know the therapeutic efficacy of the prepared nanoparticle containing etoposide. newline